Development of Neuropathic Arthropathy With Entrectinib: Case Report

Nicholas P. Giustini, MD; Hanna Oh, MD; Keith D. Eaton, MD, PhD

JTO Clinical and Research Reports (Nov 2022)

Development of Neuropathic Arthropathy With Entrectinib: Case Report

Nicholas P. Giustini, MD,
Hanna Oh, MD,
Keith D. Eaton, MD, PhD

Affiliations

Nicholas P. Giustini, MD: Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington; Corresponding author. Address for correspondence: Nicholas P. Giustini, MD, Division of Hematology, Department of Medicine, University of Washington, 1705 Northeast Pacific Street, Seattle, WA 98195.
Hanna Oh, MD: Department of Rehabilitation Medicine, University of Washington, Seattle, Washington
Keith D. Eaton, MD, PhD: Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington

Journal volume & issue: Vol. 3, no. 11
p. 100419

Abstract

Read online

TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory changes with magnetic resonance imaging revealing marrow edema. Providers should have a low threshold to investigate foot pain or gait abnormalities thoroughly with magnetic resonance imaging and referral to specialists to aid in the diagnosis of neuropathic arthropathy, with consideration to transition to an alternative agent.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords